Benitec Biopharma (BNTC) AI Stock Analysis

• Market Cap: $412.44M
• Dividend Yield: N/A
• Average Volume (3M): 133.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: 80.95%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 33,862,225
• 10 Day Avg. Volume: 96,761
• 30 Day Avg. Volume: 133,563
• PEG Ratio: 0.18
• Price to Book (P/B): 4.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.95
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 406.52
• Enterprise Value/Gross Profit: 2.48K
• Enterprise Value/Ebitda: -4.62
• 1Y Price Target: $27.00
• Price Target Upside: 121.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.02
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $12.50 ▲(2.63% Upside)

The score is held down primarily by weak financial performance (minimal revenue, large operating losses, and ongoing cash burn) and a bearish technical setup (price below major moving averages). These are partially offset by a strong, low-debt balance sheet and a positive corporate catalyst from FDA Fast Track designation for BB-301.

Positive Factors

Clinical Advancement

The advancement of the BB-301 clinical study with positive safety results is a promising development, potentially improving market position and offering strategic growth prospects.

Strong Equity Position

A strong equity position with minimal leverage provides financial stability, reducing risk and offering a solid foundation for future growth initiatives.

Proprietary Technology

The proprietary ddRNAi technology offers a unique competitive advantage in gene therapy, potentially leading to breakthrough treatments and partnerships.

Negative Factors

Negative Cash Flow

Negative cash flow indicates ongoing cash burn, which could limit the company's ability to fund operations and strategic initiatives without additional financing.

Declining Revenue

Inconsistent revenue growth and significant net losses reflect challenges in generating sales, impacting the company's ability to achieve sustainable profitability.

Negative Margins

Negative profit margins highlight operational inefficiencies and financial challenges, which could hinder long-term viability and investor confidence.

Benitec Biopharma Business Overview & Revenue Model

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

How the Company Makes Money

Benitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary

Overall financial quality is weak: revenue remains minimal (~$0.6M TTM) with deeply negative profitability (TTM EBIT about -$50.8M) and continued cash burn (TTM operating cash flow about -$22.7M). The main offset is a strong, low-leverage balance sheet (debt-to-equity ~0.01), but persistent losses (TTM ROE around -46%) threaten longer-term sustainability.

Income Statement

Operating performance remains weak. Revenue is minimal in TTM (Trailing-Twelve-Months) (~$0.6M) and was effectively zero in the last two annual periods, highlighting limited commercial scale. Profitability is deeply negative, with large operating losses (TTM EBIT about -$50.8M) and sharply negative net margin, indicating a high cost base relative to revenue. The main positive is that gross profit is positive in TTM, but it is far too small to offset operating expenses, keeping overall earnings firmly in the red.

Balance Sheet

The balance sheet is a relative strength. Leverage is very low in TTM (Trailing-Twelve-Months), with debt-to-equity around 0.01 and total debt under $1M against roughly $94M of equity, suggesting meaningful financial flexibility. Total assets are also sizable (~$96M). The key weakness is ongoing losses translating into negative returns on equity (TTM ROE around -46%), which can erode the equity base over time if losses persist.

Cash Flow

Cash generation is pressured by sustained cash burn. TTM (Trailing-Twelve-Months) operating cash flow is about -$22.7M and free cash flow is similarly negative, indicating the business is consuming cash to fund operations. Free cash flow also deteriorated versus the prior period (negative growth). A modest positive is that free cash flow broadly tracks net loss (cash burn roughly in line with reported losses), but the overall trajectory still points to continued funding needs absent a step-up in revenue or reduced spend.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	556.00K	0.00	0.00	75.00K	73.00K	59.00K
Gross Profit	91.00K	-396.00K	-343.00K	-306.00K	64.00K	-64.00K
EBITDA	-48.93M	-41.70M	-21.41M	-19.15M	-17.85M	-13.45M
Net Income	-46.42M	-37.92M	-21.75M	-19.56M	-18.21M	-13.88M
Balance Sheet
Total Assets	96.03M	99.59M	52.21M	4.46M	5.97M	21.38M
Cash, Cash Equivalents and Short-Term Investments	94.48M	97.74M	50.87M	2.48M	4.06M	19.77M
Total Debt	817.00K	849.00K	284.00K	559.00K	811.00K	213.00K
Total Liabilities	2.43M	2.30M	4.96M	4.26M	3.09M	1.37M
Stockholders Equity	93.60M	97.30M	47.25M	202.00K	2.88M	20.01M
Cash Flow
Free Cash Flow	-22.69M	-23.61M	-19.58M	-18.01M	-15.91M	-13.05M
Operating Cash Flow	-22.67M	-23.59M	-19.40M	-18.01M	-15.90M	-12.83M
Investing Cash Flow	-18.47K	-18.00K	-179.00K	-1.00K	-13.00K	-221.00K
Financing Cash Flow	50.56M	70.48M	68.03M	16.02M	0.00	22.52M

Benitec Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 12.18 is above the 20-day moving average (MA) of 12.16, below the 50-day MA of 12.53, and below the 200-day MA of 13.45, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.00 is Neutral, neither overbought nor oversold. The STOCH value of 54.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.

Benitec Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCKT	52 Neutral	$376.61M	-1.55	-74.88%	―	―	18.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	49 Neutral	$407.69M	-5.37	-36.94%	―	31.30%	32.79%
BNTC	48 Neutral	$412.44M	―	-43.71%	―	―	80.95%
FDMT	47 Neutral	$451.93M	-2.25	-45.38%	―	―	―
TVRD	46 Neutral	$37.24M	-0.40	-97.61%	―	-53.67%	86.75%
AURA	42 Neutral	$355.62M	-2.90	-64.26%	―	―	-11.41%

Benitec Biopharma Corporate Events

Benitec Biopharma Concludes 2025 Annual Stockholders Meeting

On December 1, 2025, Benitec Biopharma Inc. held its virtual 2025 Annual Meeting of Stockholders, where 85.06% of the company’s shares were represented. The meeting resulted in the election of directors, ratification of an independent accounting firm, and approval of executive compensation, with all proposals receiving the necessary votes for approval.

The most recent analyst rating on (BNTC) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.

Benitec Biopharma Announces $100 Million Public Offering

On November 5, 2025, Benitec Biopharma announced the pricing of a public offering of 5,930,000 shares of common stock and a concurrent registered direct offering of 1,481,481 shares, both priced at $13.50 per share. The offerings, expected to close on November 7, 2025, are projected to raise approximately $100 million in gross proceeds, which Benitec intends to use for the development of its product candidate programs and general corporate purposes. The underwriters, including Leerink Partners, TD Securities, and Evercore ISI, were granted a 30-day option to purchase an additional 889,500 shares. The offerings are part of Benitec’s strategy to strengthen its financial position and support its ongoing research and development efforts.

The most recent analyst rating on (BNTC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.

Benitec Biopharma’s BB-301 Receives FDA Fast Track

On November 2, 2025, Benitec Biopharma appointed Dr. Sharon Mates to its Board of Directors, effective November 3, 2025. Dr. Mates, known for her leadership in biotechnology, will serve as a Class I member until the 2026 annual meeting. Her appointment is expected to bolster the company’s strategic direction, particularly in advancing the BB-301 program for OPMD. Additionally, on November 3, 2025, the FDA granted Fast Track Designation to Benitec’s BB-301 for treating OPMD, a significant milestone that could expedite the development and review process of this potentially groundbreaking gene therapy.

The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.